Giredestrant cuts disease progression risk 44% in ER-positive breast cancer
Giredestrant cuts disease progression risk 44% in ER-positive breast cancer clinicaltrialvanguard.com
411 материалов по теме, собраны автоматически из проверенных источников
Giredestrant cuts disease progression risk 44% in ER-positive breast cancer clinicaltrialvanguard.com
'Cried and cried': How a breast cancer trial changed the lives of survivors ABC News & Headlines – Australian Broadcasting Corporation
Can Personalized Dosing Improve Life With Metastatic Breast Cancer? Technology Networks
SERD Combination Slows Breast Cancer After CDK4/6 Inhibitor Progression MedPage Today
Triple-Negative Breast Cancer Trials Leave Millions of Women Too Far From Care Bioengineer.org
One of the major challenges in treating the most common subtype of breast cancer (hormone receptor positive, HR+) is the emergence of resistance to treatment. In a recent study, Boston Children's Hospital researchers and colleagues discovered a new driver of resistance, pointing to a way to detect resistant cancer…
Living Three Years With Leptomeningeal Disease After Metastatic Breast Cancer Cure Today
Personalizing Breast Cancer Care at Every Step Miami Herald
The Next Era of Breast Cancer Care: Penny Kechagioglou European Medical Journal
В городскую больницу № 5 Уфы поступил новый маммограф Панорама Башкортостана
Exercise linked to better attention and memory after breast cancer News-Medical
One in three breast cancer survivors will experience cognitive problems, which can include difficulties with attention, memory, processing speed and other aspects of thinking. Researchers believe these problems can arise from a combination of treatment effects, inflammation, hormonal changes, fatigue and stress. They…
Hot Flashes From Breast Cancer Treatment May Soon Have an FDA-Approved Fix Cure Today
Patient with Breast Cancer Brain Metastases Continues to Fight as Research Advances Dana-Farber Cancer Institute
Mayo Clinic researchers have discovered distinct gut microbiome patterns in adults 50 or younger with colorectal and breast cancers compared with those diagnosed later in life—one of several findings from an analysis of stool samples from 1,364 patients across cancer types, stages and treatments. The study is…